Leathanach 1 ó 58 torthaí
Background: Among breast cancer survivors, urinary incontinence (UI) is often attributed to cancer therapy. We prospectively assessed urinary symptoms before and after (neo)adjuvant treatment of early-stage breast cancer.
Methods:
Breast cancer is the most commonly diagnosed cancer among women in the USA and the second leading cause of cancer deaths in women. Breast cancer metastases to the bladder are unusual but have been reported occasionally in the literature. The majority of the reports describe bladder metastases
Bladder metastasis from breast cancer is rare. Patients with breast cancer, in particular patients with a lobular carcinoma subtype, who present with urinary symptoms including incontinence, hematuria, dysuria, and frequency should have the possibility of bladder metastases kept in mind and
Hormone-related symptoms are common in breast cancer survivors and many aspects of these symptoms are currently under study. Reliable and valid assessment tools are needed to successfully study hormone-related symptoms in breast cancer survivors; however, no gold standard currently exists for
Tamoxifen treatment has been shown to reduce the recurrence and mortality rates in hormone receptor-positive breast cancers independent from chemotherapy. This benefit increases with the prolongation of the use of tamoxifen but with increasing side effects. In this study, we aim to Objective. Breast cancer accounts for approximately one-third of all cancers in females. Approximately 8.5 % of all central nervous system metastases are located in the spinal cord. These patients have rapidly progressing neurological deficits and require immediate examination. The aim of surgery is
An 84-year-old lady was treated for hyperosmolar hyperglycaemia with IV insulin, fluids and catheterisation for fluid balance monitoring. Trial without catheter failed as the patient complained of new-onset urinary incontinence and lack of awareness of bladder filling. In light of her breast cancer
OBJECTIVE
To compare the prevalence of urinary incontinence (UI) between Hispanic and non-Hispanic White women in a population-based study.
METHODS
The prevalence of moderate to severe UI, defined as Sandvik severity score of >or=3, was assessed in relation to ethnicity by stratification, age
Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The association between endocrine therapy and common pelvic floor disorders including urinary incontinence has rarely been evaluated. We examined urogenital and sexual side effects among women with a breast cancer diagnosis,
OBJECTIVE
To describe the development and implementation of a comprehensive menopausal assessment (CMA) and intervention program for women with a history of breast cancer.
METHODS
Published articles selected from computerized databases, conference proceedings, bibliographies of pertinent articles
BACKGROUND
Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients. The purpose of this study was to test the efficacy of a
BACKGROUND
Tamoxifen has been used in women with hormone receptor-positive breast cancer and has been shown to successfully reduce both recurrence and mortality. On the contrary, long-term use of tamoxifen has hormone-related urogenital side effects which decrease the quality of life of the
During the past decade, many medical conditions previously thought to be unmentionable are now being talked about more openly. Breast cancer, for example, has had a great deal of media attention, particularly when women in the public eye reveal that they have been diagnosed with it. This publicity
BACKGROUND
It is possible that oestrogen deficiency may be an aetiological factor in the development of urinary incontinence in women.
OBJECTIVE
To assess the effects of local and systemic oestrogens used for the treatment of urinary incontinence.
METHODS
We searched the Cochrane Incontinence Group
There is a growing use of hormone replacement therapy during menopause in the western world. Although most of epidemiologic studies have not found a cause-effect relation between this therapy and breast cancer, the fear of breast cancer related to this therapy limits its vast use. Controversy